Actinium Pharmaceuticals, Inc.
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
ATNM | NYSE
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 100 PARK AVE., 23RD FLOOR, 10017 NEW YORK
- Website:
- https://www.actiniumpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Actinium Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company pioneering the development of targeted radiotherapies for patients with unmet medical needs. The company develops Antibody Radiation-Conjugates (ARCs) to treat advanced cancers. Its clinical pipeline features Actimab-A, a CD33-targeting therapeutic for relapsed or refractory Acute Myeloid Leukemia (r/r AML), and ATNM-400, a first-in-class, non-PSMA radiotherapy for prostate cancer. Actinium leverages its proprietary Actinium-225 manufacturing technology to support its expanding portfolio of targeted conditioning and radiotherapy programs, aiming to improve outcomes for patients with limited treatment options.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Actinium Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Actinium Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Actinium Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
